抗生素在现代hidradenitis suppurativa治疗中的角色
Is There Still a Place for Antibiotics in Modern Hidradenitis Suppurativa Treatment?
随着hidradenitis suppurativa治疗选项的扩展,抗生素的作用受到质疑。专家认为抗生素应作为短期治疗或桥接疗法使用,以减少长期使用导致的耐药风险。四环素类抗生素如多西环素和米诺环素因其抗炎作用仍可能长期受益,但不建议单独使用,而是在生物制剂治疗开始前作为辅助。
— Megan Rogge, MD, discusses the shift toward shorter courses and biologic bridging
by Gregory Laub, Senior Director, Video, MedPage Today
November 11, 2026 • 2 min read
As treatment options for hidradenitis suppurativa (HS) continue to expand, one of the questions discussed at the European Academy of Dermatology and Venereology meeting in Vienna was how antibiotics can still be beneficial in disease management, particularly as biologics and other targeted therapies take on a larger role.
In this exclusive MedPage Today video, Megan Rogge, MD, of McGovern Medical School at UTHealth Houston, discusses how she thinks about antibiotic use moving forward, including the shift toward shorter courses, their role as bridge therapy, and the importance of limiting long-term exposure to reduce resistance risk.
Following is a transcript of her remarks:
I think that we are getting away from treating HS as an infection. So, of course, the microbiome is really important and definitely sometimes infections can drive flares. However, it's not very common. A lot of hidradenitis lesions are sterile, and therefore we're getting away from antimicrobial and we're really focusing more on anti-inflammatory.
So, the tetracycline-class antibiotics such as doxycycline, minocycline, these are going to be still potentially beneficial for the patient in the long term because they have these anti-inflammatory effects. But we're not using them as monotherapy as much anymore because again, as soon as we are recognizing that there is moderate disease, we are going to be really initiating more biologic therapy and potentially some of these other things as they're approved. So, the bridging aspect is absolutely true. Maybe we'll be starting with antibiotics along with a biologic and then allowing that biologic some time to take effect.
And, yes, I think we also want to consider shorter courses of antibiotics for patients. So, the combination of clindamycin [and] rifampin, for instance, has been studied and that's really just for 10 to 12 weeks. And so, it's really kind of more of a short-term treatment and not a long-term treatment option we want patients on. Similarly, ertapenem is really more of a rescue treatment. And, again, it's a short and defined course.
We don't want to put these patients at risk for multi-resistant bacteria, and therefore using antibiotics in shorter courses as bridge therapy, or primarily for other anti-inflammatory effects, are really what we are moving towards with hidradenitis.
来源:MedPage Today · medpagetoday.com